Navigation Links
Adding Vitamin B12 to Standard Drugs Might Help Fight Hepatitis C
Date:7/18/2012

WEDNESDAY, July 18 (HealthDay News) -- Taking vitamin B12 supplements may help boost the effectiveness of antiviral drugs for patients infected with hepatitis C virus, a new study suggests.

This effect was especially strong in patients whose infection was particularly tough to treat, note Italian researchers led by Dr. Gerardo Nardone of the University of Naples.

According to Nardone's team, the standard treatment of two drugs -- interferon (peg IFN) and ribavarin -- clears the virus in about 50 percent of patients infected with strain 1 of the virus and 80 percent of those infected with strains 2 or 3.

However, that means that the treatment still does not clear hepatitis C in about half of all patients infected with the virus or if the infection returns once treatment ends.

The new study included 94 patients with hepatitis C infection who were randomly assigned to receive standard treatment with antiviral drugs or standard treatment plus 5,000 micrograms of vitamin B12 every month for between six and 12 months.

The ability of the patients' bodies to clear the virus was assessed after one month and three months (dubbed a "rapid viral response"), at the end of treatment ("complete early viral response"), and six months after the end of treatment ("sustained viral response").

After one month of treatment, there was no difference in response between patients receiving standard treatment and those receiving standard treatment plus vitamin B12. However, patients receiving vitamin B12 showed significantly greater response at all of the other time points, particularly by six months after the end of treatment.

Overall, adding vitamin B12 to standard treatment strengthened the rate of long-term, sustained viral response by 34 percent, the researchers noted.

The investigators also found that the increased response associated with taking vitamin B12 was particularly strong in patients with the type 1 strain of hepatitis C and in those with higher levels of infection.

The addition of vitamin B12 to treatment with current antiviral drugs offers a safe and inexpensive option until new-generation antiviral drugs become available or if those new treatments are too expensive, the researchers concluded.

Two U.S. experts were more dubious as they weighed in on the findings.

Dr. David Bernstein is chief of the division of hepatology at North Shore University Hospital in Manhasset, N.Y. He noted that for patients with strains 2 and 3 of the virus, adding vitamin B12 "was not of any value."

As for patients with strain 1 of the virus, Bernstein said the standard of care is now a three-drug regimen of pegylated interferon plus ribavirin plus a protease inhibitor drug, not the two-drug regimen used in this study. So, "while the information presented in this study is interesting in genotype [strain] 1 patients . . . what would be more interesting would be the addition of vitamin B12 to the current standard of care therapy of pegylated interferon plus ribavirin plus a protease inhibitor," Bernstein said.

Dr. Peter Malet, director of the Center for Liver Diseases, and a hepatologist at Winthrop-University Hospital in Mineola, N.Y., agreed.

"This research is very preliminary; it needs to be confirmed or refuted by other studies," he said.

The study was published online July 17 in the journal Gut.

More information

The U.S. National Institute of Allergy and Infectious Diseases has more about hepatitis C.

-- Robert Preidt

SOURCES: David Bernstein, M.D, chief, division of hepatology, North Shore University Hospital, Manhasset, N.Y; Peter Malet, M.D, director, Center for Liver Diseases, and hepatologist, Winthrop-University Hospital, Mineola, N.Y.; Gut, news release, July 17, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
2. Vitamin E may lower liver cancer risk
3. Increase in RDA for vitamin C could help reduce heart disease, stroke, cancer
4. Vitamin D deficiency and poorer lung function in asthmatic children treated with steroids
5. Higher but not lower doses of vitamin D are effective in fracture risk reduction in older adults
6. Higher Doses of Vitamin D Prevent Fractures in Older Women
7. Low Vitamin D Levels Linked to Weight Gain in Older Women
8. 2 new vitamin D blood tests are often highly inaccurate, researchers say
9. The Gluten Free Society Talks About Vitamin Contamination
10. Older Women Should Not Take Calcium, Vitamin D: Task Force
11. Older adults may need more vitamin D to prevent mobility difficulties
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Adding Vitamin B12 to Standard Drugs Might Help Fight Hepatitis C
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
Breaking Medicine Technology: